1 It has been associated with
anti-obesity actions in obese rats.
2 a and that this effect may contribute to its
anti-obesity actions.
3 Furthermore, quercetin has
anti-obesity activity through mitogen-activated protein
4 ordi (thunder god vine) plant, is a powerful
anti-obesity agent.
5 uoromethylated analog of a hypolipidemic and
anti-obesity agent.
6 beta 3-selective agonists will be effective
anti-obesity agents in humans is presently under investi
7 velopment of drugs that may become effective
anti-obesity agents in humans.
8 hemical pathways rendering monotherapy-based
anti-obesity agents relatively ineffective.
9 receptor (TR) agonists as lipid-lowering and
anti-obesity agents remains largely unexplored in humans
10 are being assessed as potential therapeutic
anti-obesity agents, and both potently reduce food intak
11 the pursuit toward development of effective
anti-obesity agents.
12 testosterone levels, and is advertised as an
anti-obesity and anti-aging supplement capable of improv
13 for the development of novel antibiotics and
anti-obesity and anti-cancer agents.
14 in adult humans and may be exploited for its
anti-obesity and anti-diabetes actions.
15 ne secreted by adipocytes, and known for its
anti-obesity and anti-diabetic properties.
16 Inhibition of PAI-1 might provide a novel
anti-obesity and anti-insulin resistance treatment.
17 agy by disrupting the atg7 gene has a unique
anti-obesity and insulin sensitization effect.
18 The
anti-obesity and microbiota-modulating effects are trans
19 olated from the WEGL extract produce similar
anti-obesity and microbiota-modulating effects.
20 alls into question the potential value of an
anti-obesity approach that is based on administration of
21 s what the future landscape of neurohormonal
anti-obesity combinations may hold.
22 Anti-obesity drug development is thus focusing on target
23 ature should be considered when assessing an
anti-obesity drug in mice, particularly agents acting on
24 impact of a prescan meal ("satiety") and the
anti-obesity drug sibutramine, a serotonin and noradrena
25 t and has thus received much attention as an
anti-obesity drug target.
26 iscrepancy remain undetermined, an effective
anti-obesity drug ultimately must produce its effects ac
27 these, SR141716A was marketed as a promising
anti-obesity drug, but was withdrawn from the market bec
28 ded with the following treatment categories:
anti-obesity drugs (3 arms; n = 658), meal replacements
29 Commercial
anti-obesity drugs acting in the gastrointestinal tract
30 on can be a barrier to greater acceptance of
anti-obesity drugs as appropriate options for treatment.
31 of DmrB could help guide the development of
anti-obesity drugs based on modification of the ecology
32 ciated with adverse health consequences, and
anti-obesity drugs can help people to lose weight, very
33 Several
anti-obesity drugs have been approved in the USA, Europe
34 Compared with controls,
anti-obesity drugs improved weight-loss maintenance by 3
35 , and beta3-selective agonists are effective
anti-obesity drugs in rodents.
36 e and remains a great unmet medical need for
anti-obesity drugs that increase energy expenditure by a
37 ormation is important for the development of
anti-obesity drugs that target ghrelin signaling.
38 ion in three studies, one of which also used
anti-obesity drugs, and bariatric surgery in four.
39 The objective was to evaluate the effects of
anti-obesity drugs, diet, or exercise on weight-loss mai
40 Anti-obesity drugs, meal replacements, and high-protein
41 otential novel target for the development of
anti-obesity drugs.
42 f FXR in the intestine could be a target for
anti-obesity drugs.
43 omeostasis in humans, and offer a target for
anti-obesity drugs.
44 ad to the development of systemically active
anti-obesity drugs.
45 nd interleukin 1beta (IL-1beta) may exert an
anti-obesity effect in the CNS during health.
46 OH)2-D3-induced [Ca2+]i may contribute to an
anti-obesity effect of dietary calcium, and the mVDR may
47 ptosis and thereby further contributes to an
anti-obesity effect of dietary calcium.
48 Mechanistic studies indicated that
anti-obesity effect of FGFR4 ASO was mediated at least i
49 The
anti-obesity effect was accompanied by improvement in pl
50 nsulin sensitization, anti-inflammatory, and
anti-obesity effects and is therefore emerging as a new
51 vivo mechanistic studies indicated that the
anti-obesity effects of beta-LGNDs were due to indirect
52 ipocyte UCP2 expression, indicating that the
anti-obesity effects of dietary calcium are mediated by
53 provide a putative mechanism to explain the
anti-obesity effects of tea.
54 gesting that the intestinal FXR mediates the
anti-obesity effects of tempol.
55 administration of IL-33 results in multiple
anti-obesity effects, including the reversal of VAT infl
56 manipulated, had pronounced pro-obesity and
anti-obesity effects.
57 y of first-order neurons initiating leptin's
anti-obesity effects.
58 osed that leptin serves a primary role as an
anti-obesity hormone, but this role is commonly thwarted
59 des, which reveals their potential to act as
anti-obesity ingredients.
60 GF21 is a stress-induced hormone with potent
anti-obesity,
insulin-sensitizing, and hepatoprotective
61 a metabolomics-driven effort to uncover the
anti-obesity mechanism(s) of xanthohumol (XN), a prenyla
62 as important health-related implications for
anti-obesity medical therapy and lipodystrophy.
63 The
anti-obesity medication rimonabant, an antagonist of can
64 d potential alternatives, currently approved
anti-obesity medications and best practices to individua
65 Although few promising
anti-obesity medications are in the drug-development pip
66 ts will likely herald a second generation of
anti-obesity medications over the next decade.
67 hat inactivate perilipin may prove useful as
anti-obesity medications.
68 ated protein (FTO) is a potential target for
anti-obesity medicines.
69 yte development inhibitors could be a viable
anti-obesity therapeutic.
70 carboxylase may be a suitable target for an
anti-obesity therapeutic.
71 ary neurotrophic factor (CNTF), as potential
anti-obesity therapeutics.
72 ity of BAT makes it an attractive target for
anti-obesity therapies.
73 ilities for future development of successful
anti-obesity therapies.
74 of body weight and hold potential as a novel
anti-obesity treatment.
75 may prove to be effective and more selective
anti-obesity treatments.